Two studies are designed to evaluate the DLTs and the ORR (NCT02974725 and NCT04417621, respectively) during combination therapy with Ribociclib and LXH254, a BRAF and CRAF inhibitor with antitumor activity in MAPK-driven tumor models [100]. The gene discussed is BRAF; the disease is neoplasm.